To provide a novel treatment for severe-to-profound sensorineural hearing loss associated with biallelic variants in the OTOF gene.
Key Findings:
16 of 20 patients met the primary endpoint of improvement in pure tone audiometry thresholds to 70 decibel hearing level or better at 24 weeks.
14 of 20 patients showed auditory brainstem responses at 90 decibel hearing level or better at 24 weeks.
5 of 12 patients maintained hearing thresholds within the normal range by week 48.
Interpretation:
The therapy offers a potential breakthrough for patients with OTOF-related hearing loss, which currently lacks effective treatment options.
Limitations:
The therapy is not recommended for patients with inaccessible inner ear or those with prior cochlear implants.
Continued approval is dependent on further confirmation of clinical benefits.
Conclusion:
Lunsotogene parvec-cwha represents a significant advancement in treating a rare form of hearing loss, pending further validation of its long-term efficacy.
